265 Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort

• Luc Dirix,
• Frank Beier,
• Alain Ravaud,
• Theodore Gourdin,
• Jean-Laurent Deville,
• Marco Maruzzo,
• XiaoZhe Wang,
• Yulia Vugmeyster,
• Jeorg Seebeck,
• Sarah Chennoufi

Affiliations

Luc Dirix

Aff5 Saint-Augustinus Hospital Antwerp Belgium

Frank Beier

Bone and Joint Institute, Western University, London, Ontario, Canada

Alain Ravaud

Department of Medical Oncology, Hôpital Saint-André, University of Bordeaux-CHU, Bordeaux, France

Theodore Gourdin

Hematology/Oncology, The University of Oklahoma Stephenson Cancer Center, Oklahoma City, Oklahoma, USA

Jean-Laurent Deville

1La Timone Hospital, Marseille, France, Marseille, France

Marco Maruzzo

3Istituto Oncologico Veneto IOV IRCSS, Padua, Italy, Padua, Italy

XiaoZhe Wang

7EMD Serono Research and Development Institute, Inc., Billerica, Massachusetts, USA; a business of Merck KGaA, Darmstadt, Germany, Billerica, MA, USA

Yulia Vugmeyster

7EMD Serono Research and Development Institute, Inc., Billerica, Massachusetts, USA; a business of Merck KGaA, Darmstadt, Germany, Billerica, MA, USA

Jeorg Seebeck

8Merck KGaA, Darmstadt, Germany, Darmstadt, Germany

Sarah Chennoufi

8Merck KGaA, Darmstadt, Germany, Darmstadt, Germany